These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 16583340)

  • 1. [The PPARgamma receptor agonists and prevention of cardio-vascular complications in patients with type 2 diabetes. The results of the PROactive study].
    Szymborska-Kajanek A; Strojek K
    Kardiol Pol; 2006 Mar; 64(3):322-5; discussion 325-6. PubMed ID: 16583340
    [No Abstract]   [Full Text] [Related]  

  • 2. [PPAR agonists do not come up to expectations. Hope about the preventive effect in type 2 diabetes has come to nought].
    Olsson AG
    Lakartidningen; 2006 Aug 30-Sep 5; 103(35):2454-5. PubMed ID: 17002160
    [No Abstract]   [Full Text] [Related]  

  • 3. A lesson in moderation: applying pharmacodynamics to clarify the relationship between thiazolidinediones and adverse vascular outcomes in type 2 diabetes.
    Lehmann DF; Lohray BB
    J Clin Pharmacol; 2008 Aug; 48(8):999-1002. PubMed ID: 18650500
    [No Abstract]   [Full Text] [Related]  

  • 4. Dual PPAR alpha/gamma agonists: promises and pitfalls in type 2 diabetes.
    Ahmed I; Furlong K; Flood J; Treat VP; Goldstein BJ
    Am J Ther; 2007; 14(1):49-62. PubMed ID: 17303976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Glitazones critically evaluated].
    Schernthaner G
    Dtsch Med Wochenschr; 2007 Dec; 132(49):2619. PubMed ID: 18050024
    [No Abstract]   [Full Text] [Related]  

  • 6. [Too positive comment on glitazones].
    Lindberg M
    Ugeskr Laeger; 2007 Feb; 169(8):733; author reply 733. PubMed ID: 17338040
    [No Abstract]   [Full Text] [Related]  

  • 7. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.
    Yu J; Jin N; Wang G; Zhang F; Mao J; Wang X
    Metabolism; 2007 Oct; 56(10):1396-401. PubMed ID: 17884451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PROactive Study: (r)evolution in the therapy of diabetes?
    Ceriello A
    Diabet Med; 2005 Nov; 22(11):1463-4. PubMed ID: 16241907
    [No Abstract]   [Full Text] [Related]  

  • 9. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
    Touyz RM; Schiffrin EL
    Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Glitazone - mailing no 1. In response to DMW 49/2007].
    Traut V
    Dtsch Med Wochenschr; 2008 Feb; 133(6):261; author reply 262-3. PubMed ID: 18236356
    [No Abstract]   [Full Text] [Related]  

  • 11. Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism.
    Fogo AB
    Curr Opin Nephrol Hypertens; 2008 May; 17(3):282-5. PubMed ID: 18408479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Future directions for insulin sensitizers in disease prevention.
    Colca JR
    Curr Opin Investig Drugs; 2007 Sep; 8(9):707-10. PubMed ID: 17729181
    [No Abstract]   [Full Text] [Related]  

  • 13. Peroxisome proliferator-activated receptor gamma agonists: their role as vasoprotective agents in diabetes.
    Blaschke F; Caglayan E; Hsueh WA
    Endocrinol Metab Clin North Am; 2006 Sep; 35(3):561-74, ix. PubMed ID: 16959586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thiazolidinediones.
    Yki-Järvinen H
    N Engl J Med; 2004 Sep; 351(11):1106-18. PubMed ID: 15356308
    [No Abstract]   [Full Text] [Related]  

  • 15. Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.
    Krentz A
    Diabetes Metab Res Rev; 2009 Feb; 25(2):112-26. PubMed ID: 19219860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of PPAR gamma agonists on cardiovascular function in obese, non-diabetic patients.
    Panunti B; Fonseca V
    Vascul Pharmacol; 2006 Jul; 45(1):29-35. PubMed ID: 16777491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [How does the PROactive Study change therapy of diabetes?].
    Erdmann E
    MMW Fortschr Med; 2005 Oct; 147(41):6. PubMed ID: 16270501
    [No Abstract]   [Full Text] [Related]  

  • 18. Cardiovascular risk and cardiometabolic protection: role of glitazones.
    Petrazzi L; Grassi D; Polidoro L; D'Aurelio A; Croce G; Properzi G; Tiberti S; Desideri G; Ferri C
    J Nephrol; 2008; 21(6):826-35. PubMed ID: 19034866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10).
    Wilcox R; Kupfer S; Erdmann E;
    Am Heart J; 2008 Apr; 155(4):712-7. PubMed ID: 18371481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Glitazone - mailing no 3. In response to DMW 49/2007].
    Gundel UF
    Dtsch Med Wochenschr; 2008 Feb; 133(6):261-2; author reply 262-3. PubMed ID: 18236354
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.